A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.
Also called NCT02877173
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 160 participants
- Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Registry
-
NCT02877173
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02877173. Randomized; double masking; primary purpose treatment. Start 2016-08 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
- Condition
- Arteriosclerosis Obliterans
- Intervention (Drug)
- Alprostadil Liposomes for Injection
- Intervention (Drug)
- Alprostadil Injection
- Lead sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
Record details
- Record id
cardio:ct-nct02877173- Content hash
b15bb906a79f8e41d9ac953dcb31d25c96cd9a2d1bca5079af52e617a7fb8490